Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2007

View Archived Issues

Mucosal trivalent vaccine against botulism toxin identified at DOR BioPharma

Novel agents for metabolic disorders described in recent patents

Recent patents describe new compounds targeting cardiovascular diseases

New agents for treating disorders of hemostasis reported in recent patents

HyCAMP shows greater efficacy than Camptosar in metastatic colorectal cancer

New safety data presented on Riquent

ANAVEX 1-41 and ANAVEX 2-73 show potential in preclinical Alzheimer's studies

CuraGen completes sale of 454 Life Sciences to Roche

Genzyme to acquire Bioenvision

Ranbaxy acquires 13 derma products from BMS

New phase II trial for Panzem NCD with Temodar in recurrent GBM

Fx-1006A studied for familial amyloid polyneuropathy in phase II/III study

Talima Therapeutics closes new Series B funding round

Avexa receives grant to develop new generation of HIV antiviral drugs

Primary endpoint met in pivotal study of aztreonam lysine in cystic fibrosis

Takeda licenses BioWa's Potelligent technology for antibody development

Clinical utility, tolerability of desvenlafaxine demonstrated in major depression patients

Durable fibromyalgia responses seen with pregabalin

Clinical trials in urological diseases

Preclinical data on new drugs for pulmonary inflammatory diseases

Archexin cleared to begin phase II trial in renal cell carcinoma

New European trial studies Vascular Wrap

Protherics withdraws European application for Voraxaze

Torisel approved for advanced renal cell carcinoma

Telavancin begins European review for cSSTI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.